Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or versus hydrochlorothiazide or placebo.

What Was Tested

Researchers studied Hydrochlorothiazide in this randomized controlled trial publication.

Who Took Part

The abstract describes 1039 patients taking part.

PubMed indexes the participants as adults, middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, single-blind and placebo-controlled study.

Because people in this Hydrochlorothiazide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Hydrochlorothiazide study, the assignments were hidden from both participants and investigators until the end.

In this single-blind Hydrochlorothiazide study one party knew the assignments and the other did not.

A placebo (an inactive look-alike) gave the Hydrochlorothiazide group a baseline to be compared against.

Secondary end points were the percentage achieving the target fall in SBP and the change from baseline in seated trough DBP.

Incidence and severity of adverse events and physical examination and laboratory parameters were monitored for the safety evaluation.

What Was Measured

The subject headings attached to it are Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Benzimidazoles, Benzoates, Blood Pressure, Hydrochlorothiazide and Hypertension.

What This Means in Plain Language

The paper is a randomized, double-blind and single-blind study of Hydrochlorothiazide in 1039 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2004 (Journal of hypertension), a journal based in Netherlands.

More context: all human trials.